convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 22, 1996.

A. Federal Reserve Bank of Boston (Robert M. Brady, Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02106:

1. Cambridge Bancorp, Cambridge, Massachusetts; to engage *de novo* through its subsidiary Cambridge Investment Services of New Hampshire, Inc., Concord, New Hampshire, in expanding the previously approved investment advisory activities to include the provision of discretionary investment management services to noninstitutional customers. The Board has previously found this activity to be so closely related to banking. See *Keystone Financial, Inc.*, 82 Fed. Res. Bull. 84 (1996); *CoreStates Financial Corp.*, 80 Fed. Res. Bull. 644 (1994).

B. Federal Reserve Bank of New York (Christopher J. McCurdy, Senior Vice President) 33 Liberty Street, New York, New York 10045:

1. Cooperative Centrale Raiffeisen-Boereleenbank B.A., Rabobank Nederland, Utrecht, The Netherlands; to acquire through its 51 percent owned subsidiary, Agricredit Acceptance LLC, Des Moines, Iowa, all of the assets of Agricredit Acceptance Corporation and thereby engage in: (i) receivables financing (including leasing) activities pursuant to § 225.25(b)(1) of the Board's Regulation Y; (ii) leasing activities pursuant to § 225.25(b)(5) of the Board's Regulation Y; (iii) insurance activities pursuant to § 225.25(b)(8)(i) and (ii) of the Board's Regulation Y; and (iv) data processing activities pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, August 2, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–20199 Filed 8–7–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research

Notice of Health Care Policy and Research, Special Emphasis Panel Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of August 1996:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: August 29–30, 1996, 8:00 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Conference Room TBA, Bethesda, Maryland 20814.

Open August 29, 8:00 a.m. to 8:15 a.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications proposing to conduct research on computerized decision support systems (CDSS) as a component of electronic medical record systems. The goal of this research is to assist providers' decisionmaking and to improve the cost-effective delivery of health services.

Agenda: The open session of the meeting on August 29, from 8:00 a.m. to 8:15 a.m., will be devoted to a business meeting covering administrative matters. During the closed session, the panel will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to include personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Carmen Johnson, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1449 x1613.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: August 1, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–20206 Filed 8–7–96; 8:45 am]

BILLING CODE 4160–90–M

Agency for Toxic Substances and Disease Registry

[ATSDR–109]

Availability of ATSDR Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of pending publication of Toxicological Profiles for public comment.

SUMMARY: This notice announces the status of the development of toxicological profiles scheduled for development in fiscal year 1996.

FOR FURTHER INFORMATION CONTACT: Ms. Loretta Norman, Division of Toxicology, Agency for Toxic Substances and Disease Registry, Mailstop E–29, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (404) 639–6322.

SUPPLEMENTARY INFORMATION: Section 104(i)(3) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), as amended by the Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9604 (i)(3)], directs the Administrator of ATSDR to prepare toxicological profiles of priority hazardous substances most frequently found at National Priorities List sites. New sets of profiles are normally made available on October 17th of each year. Due to uncertainty associated with the Superfund appropriations in the Federal budgetary process for fiscal year 1996, development of set 10 of the toxicological profiles was unavoidably delayed. In order to ensure that the scientific and technical integrity of the profiles is not compromised, development of set 10 will not be accelerated, but will proceed using the normal established methodology and timeframe. When set 10 is completed, it will be released in draft for public comment, as usual. At that time, a notice will be published in the Federal Register announcing availability.

Dated: August 2, 1996.

Claire V. Broome,

Deputy Administrator Agency for Toxic Substances and Disease Registry.

[FR Doc. 96–20205 Filed 8–7–96; 8:45 am]

BILLING CODE 4163–70–P

Health Care Financing Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.), the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposals for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* New Collection; *Title of Information Collection:* Evaluation of the Per-Episode Home Health Prospective Payment Demonstration; *Form No.:* HCFA–R–195; *Use:* This evaluation will collect primary data from samples of patients and from demonstration agencies to assess impacts of per-episode payment on access to care, quality of care, and the use of non-Medicare services; *Frequency:* Other (one time); *Affected Public:* Not for profit institutions, individuals and households, business or other for profit; *Number of Respondents:* 19,191; *Total Annual Hours:* 1,901.

2. *Type of Information Collection Request:* Reinstatement, with change, of a previously approved collection for which approval has expired; *Title of Information Collection:* ICR in the Hospice Care Regulation for 42 CFR@418.22, 418.24, 418.28, 418.56(b), 418.56(e)(1), 418.56(e)(3), 418.58, 418.70(d), 418.70(e), 418.74, 418.83, 418.96(b) and 418.100(b); *Form No.:* HCFA–R–30; *Use:* The HCFA-R–30 establishes standards for hospices who wish to participate in the Medicare program. The regulations establish standards for eligibility, reimbursement standards and procedures, and delineate conditions that hospices must meet to be approved for participation in Medicare. *Frequency:* On occasion; *Affected Public:* Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 1,927; *Total Annual Responses:* 1,927; *Total Annual Hours Requested:* 3,977,762.

3. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Blood Bank Inspection Checklist and Report; *Form No.:* HCFA–282; *Use:* The blood bank inspection checklist instrument is used by State agency to record data collected as part of the survey and certification process to determine compliance with the requirement for blood bank services under Clinical Laboratory Improvement Amendments; *Frequency:* Biennially; *Affected Public:* State, local, and tribal government, business or other for profit, not for profit institutions, federal government; *Number of Respondents:* 2,500; *Total Annual Hours:* 1,250.

To obtain copies of the supporting statement and any related forms, E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: August 2, 1996.

Edwin J. Glatzel,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–20235 Filed 8–7–96; 8:45 am]

BILLING CODE 4120–03–P

National Institutes of Health

Government-Owned Inventions; Availability for Licensing: HIV Protease-Related Technologies

AGENCY: National Institutes of Health.

ACTION: Notice.

The inventions referenced below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and a copy of the patent applications and issued patents may be obtained by contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7735 ext 232; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Human Immunodeficiency Virus Specific Proteolytic Enzyme and a Method for Its Synthesis and Renaturation

S Oroszlan, TD Copeland (NCI)

Serial No. 07/057,183 filed 01 Jun 87

U.S. Patent No. 5,252,477 issued 12 Oct 93

Inhibition of the HIV protease enzyme is currently an important component of combination therapies for HIV infection and AIDS. This patent discloses the amino acid and DNA sequences for natural and biologically active synthetic HIV–1 protease, as well as a method for its synthesis and purification. The synthetic enzyme, which has the correct stereospecific conformation, can be used to design HIV–1 protease inhibitors and to test their effectiveness against HIV–1. This technology is described further in the following publications: Copeland, T.D., et al., *Gene Anal Techn* 5: 109–115 (1988) and Louis, J.M., et al., *Biochem Biophys Res Comm* 164(1): 30–38 (1989). (Portfolio: Infectious Diseases—Reagents)

Human Immunodeficiency Virus Specific Proteolytic Enzyme and a Method for Its Synthesis and Renaturation

S Oroszlan, TD Copeland (NCI)

Serial No. 08/100,703 filed 30 Jul 1993

U.S. Patent No. 5,354,683 issued 11 Oct 94 (CIP of U.S. Patent 5,252,477)

Inhibition of the HIV protease enzyme is currently an important component of combination therapies for HIV infection and AIDS. This patent discloses the amino acid sequence of natural and biologically active synthetic HIV–2 protease, as well as a method for its synthesis and purification. The synthetic enzyme, which has the correct stereospecific conformation, can be used to design HIV–2 protease inhibitors and to test their effectiveness against HIV–2. This technology is described further in Copeland, T.D., et al., *Gene Anal Techn* 5: 109–115 (1988). (Portfolio: Infectious Diseases—Reagents)